Search research articles
Contact Us
Filters
Showing results (81-90 of 95) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2007
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
William E Winter, G Larry Maxwell, Chunqiao Tian, et al.
Gynecologic Oncology
|
January 21, 2012
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study
Jennifer M Rubatt, Kathleen M Darcy, Chunqiao Tian, et al.
Cancer Chemotherapy and Pharmacology
|
February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 1, 2013
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer
Stacey M Stein, Amy Tiersten, Howard S Hochster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2003
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial
Silvia C Formenti, Matthew Volm, Kristin A Skinner, et al.
Cancer Chemotherapy and Pharmacology
|
February 18, 2009
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Anna C Pavlick, Jennifer Wu, John Roberts, et al.
Annals of Surgical Oncology
|
July 20, 2011
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma
Deirdre J Cohen, Elliot Newman, Syma Iqbal, et al.
Breast Cancer Research and Treatment
|
September 30, 2010
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
Sylvia Adams, A Bapsi Chakravarthy, Martin Donach, et al.
Molecular Cancer Therapeutics
|
August 13, 2011
BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin
Tamar Safra, Lucia Borgato, Maria Ornella Nicoletto, et al.
Gynecologic Oncology
|
November 26, 2009
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study
Dennis Yi-Shin Kuo, Stephanie V Blank, Paul J Christos, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 95) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2007
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
William E Winter, G Larry Maxwell, Chunqiao Tian, et al.
Gynecologic Oncology
|
January 21, 2012
Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study
Jennifer M Rubatt, Kathleen M Darcy, Chunqiao Tian, et al.
Cancer Chemotherapy and Pharmacology
|
February 15, 2020
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up
Bhavana Pothuri, Allison L Brodsky, Joseph A Sparano, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 1, 2013
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer
Stacey M Stein, Amy Tiersten, Howard S Hochster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2003
Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial
Silvia C Formenti, Matthew Volm, Kristin A Skinner, et al.
Cancer Chemotherapy and Pharmacology
|
February 18, 2009
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Anna C Pavlick, Jennifer Wu, John Roberts, et al.
Annals of Surgical Oncology
|
July 20, 2011
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma
Deirdre J Cohen, Elliot Newman, Syma Iqbal, et al.
Breast Cancer Research and Treatment
|
September 30, 2010
Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival
Sylvia Adams, A Bapsi Chakravarthy, Martin Donach, et al.
Molecular Cancer Therapeutics
|
August 13, 2011
BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin
Tamar Safra, Lucia Borgato, Maria Ornella Nicoletto, et al.
Gynecologic Oncology
|
November 26, 2009
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study
Dennis Yi-Shin Kuo, Stephanie V Blank, Paul J Christos, et al.
Page
of 10